Clinical trial
Prospective Randomized Study Comparing the Efficacy and Safety of Refralon and Amiodarone in Cardioversion in Patients With Paroxysmal Atrial Fibrillation and Flutter
NCT05445297 is registered in ClinicalTrials.gov with National Medical Research Center for Cardiology, Ministry of Health of Russian Federation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective Randomized Study Comparing the Efficacy and Safety of Refralon and Amiodarone in Cardioversion in Patients With Paroxysmal Atrial Fibrillation and Flutter
- Lead sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- January 26, 2022
- Completion date
- June 30, 2023
- Enrollment
- 60 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
atrial fibrillation paroxysmal